News & Events
-
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.
-
September 8, 2022
C-Path’s Kristen Swingle Named President
Swingle joined C-Path in 2019 and was named interim president in 2021 TUCSON, Ariz., Sept. 8, 2022 — Critical Path Institute (C-Path) today announced that its Chief Operating Officer (COO) and Interim President, Kristen Swingle, M.S., has been named COO and President, effective immediately. Swingle has filled the interim President role since 2021, stewarding C-Path... -
December 17, 2018
CPTR Newsletter – December 2018
CPTR Newsletter – December 2018 In this issue: In the Spotlight: TB-ReFLECT Manuscript Published Updates to the TB-PACTS Clinical Trial Data Repository Project Highlights: Application of the HFS-TB to Inform Regimen Development Programs Collaboration to Expand ReSeqTB Clinical Data Sets Supporting Global Surveillance of TB Resistance Progress with Regulatory Authorities LAM Biomarker Notes... -
April 26, 2018
CPTR Newsletter – April 2018
CPTR Newsletter – April 2018 In this issue: ReSeqTB to be Adopted for WHO Surveillance of Drug-Resistant TB New Collaborations Expand TB-PACTS Database and Leverage Data for Analyses CPTR Workgroup Works to Advance Regulatory Qualification of LAM, a Promising New Biomarker TB-PBPK Model Progresses Toward EMA and FDA Qualification TB-ReFLECT Update: A Collaborative Effort... -
March 24, 2018
Global Health Partners Accelerate Uptake of Genetic Sequencing for Surveillance And Diagnosis Of Drug-Resistant Tuberculosis
WHO adopts ReSeqTB as bioinformatics platform for TB surveillance, enabling the global scale-up of culture-free, drug-resistant Mycobacterium tuberculosis surveillance programs based on sequencing technologies Renewed funding from the Bill & Melinda Gates Foundation has been applied for to support FIND, C-Path, and WHO to take ReSeqTB to the next level as part...